A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
Public ClinicalTrials.gov record NCT07629960. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1/2, Open-Label, Dose-Escalation, Dose-Enrichment, and Dose-Expansion Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of BLU-924 (SAR449336) as Monotherapy and Combination Therapy in Participants With Advanced Pancreatic Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer Harboring KRAS Mutations
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
A first in human study to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of BLU-924 / SAR449336, a pan-KRAS inhibitor, in participants with advanced Pancreatic Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer harboring KRAS mutations.
Study identification
- NCT ID
- NCT07629960
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 265 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 4, 2026 (Actual)
- Primary completion
- Sep 2029 (Estimated)
- Completion
- Jul 2031 (Estimated)
- Last update posted
- Sep 21, 2026
2026 – 2031
United States locations
- U.S. sites
- 10
- U.S. states
- 9
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Florida Cancer Specialists & Research Institute - Sarasota | Sarasota | Florida | 34242 | Recruiting |
| Moffitt Cancer Center | Tampa | Florida | 33612 | Recruiting |
| Mary Bird Perkins Cancer Center | Baton Rouge | Louisiana | 70809 | Not yet recruiting |
| Massachusetts General Hospital - Main Campus | Boston | Massachusetts | 02114 | Not yet recruiting |
| University of Michigan Medical School Rogel Cancer Center | Ann Arbor | Michigan | 48109-5843 | Not yet recruiting |
| Hackensack University Medical Center | Hackensack | New Jersey | 07601-2191 | Not yet recruiting |
| NYU Langone Health Perlmutter Cancer Center | New York | New York | 10016 | Not yet recruiting |
| Tennessee Oncology, PLLC | Nashville | Tennessee | 37203 | Not yet recruiting |
| The University of Texas MD Anderson Cancer Center - Texas Medical Center | Houston | Texas | 77030 | Not yet recruiting |
| Next Oncology Virginia Cancer Specialist | Fairfax | Virginia | 22031 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 6 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07629960, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 21, 2026 · Synced Oct 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT07629960 live on ClinicalTrials.gov.